Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis. So, if you’re still on the fence about whether Novo Nordisk A/S (ADR) is ...

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes ...

Novo Nordisk is a great business, but its dividend profile isn't nearly as impressive. That contrasts with AbbVie's dividend record, which has proven excellent over time. AbbVie's fundamentals ...

Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.76%.

Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. self-regulatory body found fault with Novo’s support for U.K pharmacy chains’ weight management services, leading its ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) is a terrific stock for many reasons. The company continues to deliver excellent financial results thanks to a lineup of medicines with incredibly ...

After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel hemophilia treatment concizumab. Meanwhile, PTC Therapeutics' troubled ...